mTOR inhibitors in cancer therapy [version 1; referees: 3 approved]

Jianling Xie, Xuemin Wang, Christopher G. Proud

Research output: Contribution to journalReview articlepeer-review

73 Citations (Scopus)

Abstract

The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers. Inhibiting mTORC1 signaling has therefore attracted great attention as an anti-cancer therapy. However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.

Original languageEnglish
Article number2078
Number of pages11
JournalF1000Research
Volume5
DOIs
Publication statusPublished - 2016
Externally publishedYes

Keywords

  • mTor
  • Cancer Therapy
  • Inhibitors

Fingerprint Dive into the research topics of 'mTOR inhibitors in cancer therapy [version 1; referees: 3 approved]'. Together they form a unique fingerprint.

Cite this